TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update
TG Therapeutics (NASDAQ: TGTX) has scheduled a conference call for Monday, March 3, 2025, at 8:30 AM ET to discuss their fourth quarter and full year 2024 financial results, along with providing a business outlook for 2025.
The call will be hosted by Michael S. Weiss, Chairman and Chief Executive Officer. Participants can join via phone using the following numbers:
- U.S.: 1-877-407-8029
- Outside U.S.: 1-201-689-8029
A live webcast will be available on the Events page in the Investors & Media section of www.tgtherapeutics.com, with an audio recording accessible for 30 days after the call. Financial results will be released via press release before the call.
TG Therapeutics (NASDAQ: TGTX) ha programmato una conferenza telefonica per lunedì 3 marzo 2025, alle 8:30 AM ET, per discutere i risultati finanziari del quarto trimestre e dell'intero anno 2024, oltre a fornire una prospettiva aziendale per il 2025.
La chiamata sarà condotta da Michael S. Weiss, Presidente e Amministratore Delegato. I partecipanti possono unirsi tramite telefono utilizzando i seguenti numeri:
- U.S.: 1-877-407-8029
- Fuori dagli Stati Uniti: 1-201-689-8029
Una diretta streaming sarà disponibile nella pagina Eventi nella sezione Investitori e Media di www.tgtherapeutics.com, con una registrazione audio accessibile per 30 giorni dopo la chiamata. I risultati finanziari saranno pubblicati tramite comunicato stampa prima della chiamata.
TG Therapeutics (NASDAQ: TGTX) ha programado una conferencia telefónica para el lunes 3 de marzo de 2025, a las 8:30 AM ET, para discutir sus resultados financieros del cuarto trimestre y del año completo 2024, además de proporcionar una perspectiva empresarial para 2025.
La llamada será dirigida por Michael S. Weiss, Presidente y Director Ejecutivo. Los participantes pueden unirse por teléfono utilizando los siguientes números:
- EE.UU.: 1-877-407-8029
- Fuera de EE.UU.: 1-201-689-8029
Una transmisión en vivo estará disponible en la página de Eventos en la sección de Inversores y Medios de www.tgtherapeutics.com, con una grabación de audio accesible durante 30 días después de la llamada. Los resultados financieros se publicarán a través de un comunicado de prensa antes de la llamada.
TG Therapeutics (NASDAQ: TGTX)는 2025년 3월 3일 월요일 오전 8시 30분 ET에 2024년 4분기 및 전체 연도 재무 결과에 대해 논의하고 2025년 사업 전망을 제공하기 위한 컨퍼런스 콜을 예정했습니다.
이 통화는 Michael S. Weiss 회장 겸 CEO가 진행합니다. 참가자는 다음 번호를 사용하여 전화로 참여할 수 있습니다:
- 미국: 1-877-407-8029
- 미국 외: 1-201-689-8029
라이브 웹캐스트는 www.tgtherapeutics.com의 투자자 및 미디어 섹션의 이벤트 페이지에서 제공되며, 통화 후 30일 동안 오디오 녹음에 접근할 수 있습니다. 재무 결과는 통화 전에 보도 자료를 통해 발표됩니다.
TG Therapeutics (NASDAQ: TGTX) a programmé une conférence téléphonique pour le lundi 3 mars 2025, à 8h30 ET, afin de discuter de ses résultats financiers du quatrième trimestre et de l'année 2024, ainsi que de fournir une perspective commerciale pour 2025.
La conférence sera animée par Michael S. Weiss, Président et Directeur Général. Les participants peuvent se joindre par téléphone en utilisant les numéros suivants :
- États-Unis : 1-877-407-8029
- En dehors des États-Unis : 1-201-689-8029
Un webcast en direct sera disponible sur la page Événements dans la section Investisseurs & Médias de www.tgtherapeutics.com, avec un enregistrement audio accessible pendant 30 jours après l'appel. Les résultats financiers seront publiés par communiqué de presse avant l'appel.
TG Therapeutics (NASDAQ: TGTX) hat eine Telefonkonferenz für Montag, den 3. März 2025, um 8:30 Uhr ET angesetzt, um die Finanzberichte für das vierte Quartal und das gesamte Jahr 2024 zu besprechen und einen Ausblick auf das Jahr 2025 zu geben.
Die Konferenz wird von Michael S. Weiss, Vorsitzender und CEO, geleitet. Teilnehmer können sich telefonisch unter den folgenden Nummern einwählen:
- USA: 1-877-407-8029
- Außerhalb der USA: 1-201-689-8029
Ein Live-Webcast wird auf der Veranstaltungsseite im Bereich Investoren & Medien von www.tgtherapeutics.com verfügbar sein, mit einer Audioaufnahme, die 30 Tage nach der Konferenz zugänglich ist. Die Finanzergebnisse werden vor der Konferenz per Pressemitteilung veröffentlicht.
- None.
- None.
Conference call to be held Monday, March 3, 2025, at 8:30 AM ET
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, March 3, 2025, at 8:30 AM ET to discuss results for the fourth quarter and full year 2024 and to provide a business outlook for 2025. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call.
In order to participate in the conference call, please call 1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Earnings Call. A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at www.tgtherapeutics.com, for a period of 30 days after the call.
TG Therapeutics will announce its financial results for this period in a press release to be issued prior to the call.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline of investigational medicines, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
FAQ
When is TG Therapeutics (TGTX) Q4 2024 earnings call scheduled?
How can investors access TGTX's Q4 2024 earnings call?
How long will TGTX's Q4 2024 earnings call recording be available?
What topics will be covered in TGTX's upcoming earnings call?
